Prior therapy with any JAK2 medications

Significant lung disorder or lung disease

Previous radiation therapy to chest wall or chest infection requiring antibiotic treatment within 28 days before study screening

Eye disease of the cornea

Patients requiring oxygen supplementation

Ejection fraction \<45% (ECHO/MUGA) or significant pulmonary hypertension \>40 mm Hg (by Echo/Doppler)

Forced Expiratory Volume (FEV1)/Forced Vital Capacity (FVC) \<70% predicted or \>130% predicted

Diffusing capacity of the Lung for Carbon Monoxide (DLCO) corrected for hemoglobin \<60% predicted, oxygen saturation \<88% at rest or after a 6-minute flat walk, without supplemental oxygen

Chest infection requiring antibiotics within 7 days of the first dose of Investigational product.

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

What this study is about